Long-term safety studies show generics are often as safe as brand-name drugs, but for certain medications - especially those with narrow therapeutic windows - small differences in manufacturing can lead to real health risks. Here’s what the data actually says.
READ MORE
Hospitals choose generics not just for cost, but for safety, reliability, and clinical fit. Learn how P&T committees evaluate generics using clinical data, rebate models, and supply chain risk to balance savings with patient outcomes.
READ MORE
Quality by Design (QbD) transforms generic drug development by building quality into every step, not just testing the final product. Learn how modern science-based approaches improve bioequivalence, cut approval times, and reduce costs.
READ MORE